Benzinga | Feb 10, 2021 08:47AM EST

Roth Capital Maintains Buy on Usana Health Sciences, Raises Price Target to $126

Roth Capital analyst David Bain maintains Usana Health Sciences (NYSE:USNA) with a Buy and raises the price target from $107 to $126.